Safety and Tolerability of Different Concentrations of an Ingenol Derivative Field Therapy in the Treatment of Actinic Keratosis

NCT01703078 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

Actinic Keratosis

Interventions

DRUG: Ingenol once daily for two consecutive days

Sponsor

LEO Pharma